Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 293

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

The BASILICA Trial

Open access
Khan, Jaffar M., Greenbaum, Adam B., Babaliaros, Vasilis C., Rogers, Toby, Eng, Marvin H., Paone, Gaetano, Leshnower, Bradley G., Reisman, Mark, Satler, Lowell, Waksman, Ron, Chen, Marcus Y., Stine, Annette M., Tian, Xin, Dvir, Danny, Lederman, Robert J.·2019·JACC: Cardiovascular Interventions

Abstract

OBJECTIVES The BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational device exemption trial was a prospective, multicenter, single-arm safety and feasibility study. BACKGROUND Coronary artery obstruction is a rare but devastating complication of transcatheter aortic valve replacement (TAVR). Current stent-based preventative strategies are suboptimal. Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction during TAVR (BASILICA) is a novel transcatheter technique performed immediately before TAVR to prevent coronary artery obstruction. METHODS Subjects with severe native or bioprosthetic aortic valve disease at high or extreme risk for surgery, and at high risk of coronary artery obstruction, were included. The primary success endpoint was successful BASILICA and TAVR without coronary obstruction or reintervention. The primary safety endpoint was freedom from major adverse cardiovascular events. Data were independently monitored. Endpoints were independently adjudicated. A core laboratory analyzed computed tomography images. RESULTS Between February 2018 and July 2018, 30 subjects were enrolled. Primary success was met in 28 (93%) subjects. BASILICA traversal and laceration was successful in 35 of 37 (95%) attempted leaflets. There was 100% freedom from coronary obstruction and reintervention. Primary safety was met in 21 (70%), driven by 6 (20%) major vascular complications related to TAVR but not BASILICA. There was 1 death at 30 days. There was 1 (3%) disabling stroke and 2 (7%) nondisabling strokes. Transient hemodynamic compromise was rare (7%) and resolved promptly with TAVR. CONCLUSIONS BASILICA was feasible in both native and bioprosthetic valves. Hemodynamic compromise was uncommon. Safety was acceptable and needs confirmation in larger studies. BASILICA appears effective in preventing coronary artery obstruction from TAVR in subjects at high risk. (J Am Coll Cardiol Intv 2019;12:1240–52) Published by Elsevier on behalf of the American College of Cardiology Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcin.2019.03.035

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 293

Metadata

Authors
Khan, J. M., Greenbaum, A. B., Babaliaros, V. C., Rogers, T., Eng, M. H., Paone, G., Leshnower, B. G., Reisman, M., Satler, L., Waksman, R., Chen, M. Y., Stine, A. M., Tian, X., Dvir, D., & Lederman, R. J.
Venue
JACC: Cardiovascular Interventions
Publisher
Elsevier BV
Published
2019-07
Volume
12
Issue
13
Pages
1240-1252
ISSN
  • 1876-7605 (ISSN-L)
  • 1936-8798
OpenAlex
W2952931116
Cited by
293
References
21
FWCI
24.45
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The BASILICA Trial. https://app.cochat.ai/papers/10.1016/j.jcin.2019.03.035
The paper
Khan, J. M., Greenbaum, A. B., Babaliaros, V. C., Rogers, T., Eng, M. H., Paone, G., Leshnower, B. G., Reisman, M., Satler, L., Waksman, R., Chen, M. Y., Stine, A. M., Tian, X., Dvir, D., & Lederman, R. J. (2019). The BASILICA Trial. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2019.03.035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.